research Scientific Opinion on the substantiation of a health claim related to KF2BL20 and maintenance of normal hair pursuant to Article 13(5) of Regulation (EC) No 1924/2006
KF2BL20 does not have proven benefits for maintaining normal hair.
Search
for
Sort by
Research
60-90 / 1000+ results 
research Scientific Opinion on the substantiation of a health claim related to iron and maintenance of normal hair growth pursuant to Article 13(5) of Regulation (EC) No 1924/2006
Iron intake has not been proven to maintain normal hair growth.
research Scientific Opinion on the substantiation of a health claim related to spermidine and prolongation of the growing phase (anagen) of the hair cycle pursuant to Article 13(5) of Regulation (EC) No 1924/2006
Spermidine may help extend the growth phase of hair.
research Response to comments on the Scientific Opinion on the substantiation of a health claim related to spermidine and prolongation of the growing phase (anagen) of the hair cycle pursuant to Article 13(5) of Regulation (EC) No 1924/2006
The EFSA maintained its view that spermidine's effect on hair growth is related to disease treatment and does not meet the health claim criteria.
research Re: The association of urolithiasis and androgenetic alopecia. Resorlu M, Sancak EB, Uysal F, Arslan M, Diri A, Adam G, Akbas A, Sariyildirim A, Gulpinar MT, Resorlu B. Ren Fail. 2015 Oct 13:1–5
Kidney stones and hair loss are significantly related in people under 60 years old.
research Scientific Opinion on the substantiation of a health claim related to a combination of thiamin, riboflavin, niacin, pantothenic acid, pyridoxine, D‐biotin and pumpkin seed oil and maintenance of normal hair pursuant to Article 13(5) of Regulation (EC) No 1924/2006
The combination of certain vitamins and pumpkin seed oil has not been proven to maintain normal hair.
research LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
research Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy
Some men's prostate tissues have low enzyme levels due to genetic changes, possibly affecting treatment for prostate enlargement.
research Long-term use of 5α-reductase inhibitors and the risk of male breast cancer
Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.
research A population‐based nested case–control study: the use of 5‐alpha‐reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia
Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
research Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors
Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.
research Impact of Alpha Blockers, 5-alpha Reductase Inhibitors and Combination Therapy on Sexual Function
Medications for enlarged prostate can cause sexual side effects like reduced libido, erectile dysfunction, and ejaculatory problems.
research Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors
Men using hair loss drugs like finasteride may experience sexual side effects like erectile dysfunction, but it's unclear who will be affected and when. Treating depression and sexual symptoms is suggested, as these men often have higher rates of both. More research is needed to understand why these side effects occur.
research Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?
Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.
research 술 전 5-알파환원효소억제제의 투여가 120W Greenlight TM HPS 레이저를 이용한 광선택적 전립선기화술에 미치는 영향
Taking 5-ARI before prostate laser surgery may lead to more blood changes, longer surgery, and more urinary issues.
research 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice
5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
research Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia
Higher levels of miR-1199-5p may reduce the effectiveness of certain prostate treatments.
research Macular Abnormalities Associated With 5α-Reductase Inhibitor
Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.
research Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.
research Three Considerations Before Advising 5-α-Reductase Inhibitors for Chemoprevention
5-α-reductase inhibitors don't prevent prostate cancer but may reduce unnecessary biopsies.
research Effects of 5‐alpha reductase inhibitors on lung function: A reason for discontinuation duringCOVID ‐19 pandemic?
5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.
research Intraethnic variation in steroid-5-alpha-reductase polymorphisms in prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment
Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.
research The connection of 5-alpha reductase inhibitors to the development of depression
5-alpha reductase inhibitors, like finasteride and dutasteride, may cause depression, but more research is needed to understand why.
research Possible role of 5-alpha reductase inhibitors in non-invasive bladder urothelial neoplasm: multicentre study
5-alpha reductase inhibitors may reduce bladder cancer recurrence and improve survival.
research Pathogenetic justification of the use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.
5-alpha reductase inhibitors help with benign prostatic hyperplasia but don't cure it, and more research is needed.
research HPLC characterization, molecular docking, QSAR and molecular dynamics simulation of Alstonia boonei phytochemical analogs as potent 5-alpha reductase inhibitors
Alstonia boonei phytochemicals show promise as alternative treatments for BPH with fewer side effects than current drugs.
research IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study
IsoPSA test works accurately even if patients take certain prostate medications.
research The Effects of Oral 5-alpha Reductase Inhibitors on Penile Intracavernosal Pressures and Penile Morphology in Rat Model.
Oral finasteride and dutasteride may negatively affect erectile function in rats.
research Re: Risk of Erectile Dysfunction Associated with Use of 5α-Reductase Inhibitors for Benign Prostatic Hyperplasia or Alopecia: Population Based Studies Using the Clinical Practice Research Datalink
Using finasteride for hair loss or prostate issues does not significantly raise the risk of erectile dysfunction.
research The role of 5-alpha-reductase inhibitors in active surveillance
5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.